Avalo Therapeutics, Inc.

1. 01

   Behind SPY and its sector fund XLV over 1 year

   1 month: −48.0% (SPY −1.6%, XLV +13.5%). 3 months: −62.5% (SPY −0.4%, XLV +15.5%). 1 year: −56.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: AVTX, SPY and XLV · as of 4 Nov 2026

2. 02

   8.3% above its 52-week low

   Closed at $7.07 on 4 Nov 2026: 70.9% below the 52-week high of $24.27 (7 May 2026) and 8.3% above the low of $6.53 (23 Oct 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

3. 03

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $7.07 was 49.6% below its 50-day average ($14.02) and 55.6% below its 200-day average ($15.91). It has closed below the 200-day for 39 sessions, since 11 Sep 2026. The 50-day average crossed below the 200-day on 22 Oct 2026, 9 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   13.0 days to cover short interest

   12.0M shares were sold short at the 15 Oct 2026 settlement, 22.3% of the 53.6M shares outstanding; covering them would take 13.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

5. 05

   RSI(14) at 23.3, 30 or below

   The 14-session relative strength index closed at 23.3 on 4 Nov 2026, its 10th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.

   Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

At the 4 Nov 2026 close